Showing results (81-90 of 107) with videos related to
Sort By:
Pageof 11
Transfusion|November 22, 2011
Xenotropic murine leukemia virus-related virus does not pose a risk to blood recipient safetyRoger Y Dodd, John Hackett, Jeffrey M Linnen, et al.Cytotherapy|April 10, 2022
Considerations for immune effector cell therapy collections: a white paper from the American Society for ApheresisHien D Liu, Leon Su, Jeffrey L Winters, et al.Journal of Clinical Apheresis|August 15, 2015
Report of the ASFA apheresis registry study on Wilson's diseaseHuy P Pham, Joseph Schwartz, Laura Cooling, et al.Oncotarget|December 22, 2016
CHIR99021 combined with retinoic acid promotes the differentiation of primordial germ cells from human embryonic stem cellsTingting Cheng, Kui Zhai, Yan Chang, et al.Journal of Clinical Apheresis|June 11, 2019
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special IssueAnand Padmanabhan, Laura Connelly-Smith, Nicole Aqui, et al.Transfusion|November 15, 2018
Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)Matthew S Karafin, Sylvia Tan, Christopher A Tormey, et al.Transfusion|September 12, 2015
Establishing a reentry procedure for human immunodeficiency virus screening-reactive donors in ChinaLing Li, Ting Xu, Tao Yang, et al.Journal of Clinical Apheresis|August 10, 2020
Update to the ASFA guidelines on the use of therapeutic apheresis in ANCA-associated vasculitisRasheed A Balogun, Amber P Sanchez, Reinhard Klingel, et al.Transfusion|July 7, 2020
Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donationLing Li, Xunliang Tong, Hanwei Chen, et al.Transfusion|June 4, 2020
Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, ChinaLing Li, Ru Yang, Jue Wang, et al.Pageof 11